Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Have Taylor Swift fans dubbed Flava Flav as King of the Swifties? Plus, his new partnership with Old Spice and if he will ever go back to the Olympics. Watch!
Education Reporter for The Wall Street Journal, Doug Belkin, discusses his latest piece and delves into why incoming freshmen are preferring southern schools.
Founder & CEO of FLYR, Alex Mans, joins Cheddar to talk about the current state of the airline industry and how his company is updating technology in the sky.
Spirit Halloween CEO, Steve Silverstein, stops by Cheddar to talk SNL, this year's top costume ideas and why you should watch out for Spirit Christmas. Watch!
Brooks Running SVP of Footwear, Carson Caprara, introduces the new Glycerin Max and explains how leaning into innovation helps build customer brand loyalty
